RT Journal Article
SR Electronic
T1 Are fewer cases of diabetes mellitus diagnosed in the months after SARS-CoV-2 infection?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.02.22283029
DO 10.1101/2022.12.02.22283029
A1 Reddy, Neha V
A1 Yeh, Hsin-Chieh
A1 Tronieri, Jena S
A1 Stürmer, Til
A1 Buse, John B
A1 Reusch, Jane E
A1 Johnson, Steven G
A1 Wong, Rachel
A1 Moffitt, Richard
A1 Wilkins, Kenneth J
A1 Harper, Jeremy
A1 Bramante, Carolyn T
A1 ,
YR 2022
UL http://medrxiv.org/content/early/2022/12/04/2022.12.02.22283029.abstract
AB Long-term sequelae of severe acute respiratory coronavirus-2 (SARS-CoV-2) infection may include an increased incidence of diabetes. Our objective was to describe the temporal relationship between new diagnoses of diabetes mellitus and SARS-CoV-2 infection in a nationally representative database. There appears to be a sharp increase in diabetes diagnoses in the 30 days surrounding SARS-CoV-2 infection, followed by a decrease in new diagnoses in the post-acute period, up to 360 days after infection. These results underscore the need for further investigation, as understanding the timing of new diabetes onset after COVID-19 has implications regarding potential etiology and screening and treatment strategies.Competing Interest StatementCTB is funded by the National Institute of Digestive Diabetes and Kidney Diseases K23DK124654. JST is funded by K23DK116935 National Institutes of Health (NIH). TS receives investigator-initiated research funding and support as Principal Investigator (R01 AG056479) from the National Institute on Aging (NIA) and as Co-Investigator (R01 HL118255 R01MD011680) NIH. TS also receives salary support as Director of Comparative Effectiveness Research (CER) NC TraCS Institute UNC (UL1TR002489) the Center for Pharmacoepidemiology (current members: GlaxoSmithKline UCB BioSciences Takeda AbbVie Boehringer Ingelheim) from pharmaceutical companies (Novo Nordisk) and from a generous contribution from Dr. Nancy A. Dreyer to the Department of Epidemiology University of North Carolina at Chapel Hill. TS does not accept personal compensation of any kind from any pharmaceutical company and owns stock in Novartis Roche and Novo Nordis. JBB contracted consulting fees and travel support for contracted activities are paid to the University of North Carolina by Adocia AstraZeneca Eli Lilly Intarcia Therapeutics MannKind Novo Nordisk Sanofi Senseonics and vTv Therapeutics. JBB reports grant support from AstraZeneca Dexcom Eli Lilly Intarcia Therapeutics Johnson & Johnson Lexicon NovaTarg Novo Nordisk Sanofi Theracos Tolerion and vTv Therapeutics. JBB has received fees for consultation from Anji Pharmaceuticals AstraZeneca Boehringer Ingelheim Cirius Therapeutics Inc Eli Lilly Fortress Biotech Janssen Mellitus Health Moderna Pendulum Therapeutics Praetego Stability Health and Zealand Pharma. JBB holds stock/options in Mellitus Health Pendulum Therapeutics PhaseBio Praetego and Stability Health. JBB is supported by grants from the National Institutes of Health Patient Centered Outcomes Research Institute Juvenile Diabetes Research Foundation International and the American Diabetes Association.Funding StatementThis study was funded by: National Center for Advancing Translational Sciences (U24 TR002306); Clinical and Translational Science Institute, University of Minnesota (UL1TR002494); National Institute of Diabetes and Digestive and Kidney Diseases (K23DK124654, Recipient: Carolyn T Bramante, MD, MPH)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This analysis was approved by the University of Minnesota institutional review board (STUDY00011578), which provided a waiver of consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and supplemental materials.